Woodstock Corp Has $9.34 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Woodstock Corp grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 107.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,610 shares of the biopharmaceutical company’s stock after purchasing an additional 8,589 shares during the period. Woodstock Corp’s holdings in Regeneron Pharmaceuticals were worth $9,339,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. Brighton Jones LLC increased its position in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares in the last quarter. Cresset Asset Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 668.3% in the first quarter. Cresset Asset Management LLC now owns 4,143 shares of the biopharmaceutical company’s stock worth $2,627,000 after acquiring an additional 4,872 shares in the last quarter. Raymond James Financial Inc. raised its position in shares of Regeneron Pharmaceuticals by 21.9% during the first quarter. Raymond James Financial Inc. now owns 111,509 shares of the biopharmaceutical company’s stock worth $70,722,000 after purchasing an additional 20,006 shares during the period. Steward Partners Investment Advisory LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 16.0% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 5,368 shares of the biopharmaceutical company’s stock valued at $3,405,000 after purchasing an additional 741 shares in the last quarter. Finally, Algert Global LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $288,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on REGN shares. Sanford C. Bernstein raised their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Canaccord Genuity Group raised their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday. Finally, HSBC assumed coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They issued a “buy” rating and a $255.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $779.45.

Regeneron Pharmaceuticals Stock Down 0.8%

Regeneron Pharmaceuticals stock opened at $746.36 on Wednesday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $790.98. The company has a fifty day simple moving average of $671.04 and a 200 day simple moving average of $595.57. The company has a market cap of $78.44 billion, a P/E ratio of 17.87, a price-to-earnings-growth ratio of 2.15 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business posted $12.46 EPS. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Insider Buying and Selling

In other news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.